Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11964154 
Cenni V, et al. (2002) Regulation of novel protein kinase C epsilon by phosphorylation. Biochem J 363, 537-45 11964154
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T566-p - PKCE (human)
Orthologous residues
PKCE (human): T566‑p, PKCE (mouse): T566‑p, PKCE (rat): T566‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PDK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PDK1 (human) pharmacological activator of upstream enzyme, transfection of inactive enzyme, phospho-antibody, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
bisindolylmaleimide no change compared to control
okadaic acid increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T710-p - PKCE (human)
Orthologous residues
PKCE (human): T710‑p, PKCE (mouse): T710‑p, PKCE (rat): T710‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bisindolylmaleimide decrease

S729-p - PKCE (human)
Orthologous residues
PKCE (human): S729‑p, PKCE (mouse): S729‑p, PKCE (rat): S729‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP2CA (human)
KINASE PKCE (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCE (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of inactive enzyme, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
bisindolylmaleimide decrease
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.